Home › Idiopathic Pulmonary Fibrosis › NCT06853145
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RecruitingEarly phase 1
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Able to provide informed consent 18 years of age or greater Clinical diagnosis of IPF Exclusion Criteria: * Continuous oxygen use at home * Oxygen saturation less than 92% on the day of MRI procedure * Pregnancy or lactation * Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded. * History of congenital cardiac disease, chronic renal failure, or cirrhosis. • Chest circumference greater than that of the xenon MR and/or helium coil. The circumference of the coil is approximately 42 inches. * Inability to understand simple instructions or to hold still for approximately 10-15 seconds. * History of respiratory infection within 2 weeks prior to the MR scan * History of MI, stroke and/or poorly controlled hypertension.
About the study
Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.
What is being tested
- Hyperpolarized Xe129 (drug)
Sponsor: University of Virginia · Participants: 6 · Started: May 1, 2025
Contact the study team
- Roselove Asare, MA · Phone: 4342436074
Official record on ClinicalTrials.gov — NCT06853145
Locations in the U.S.
| Virginia | Snyder Building 480 Ray C. Hunt Drive, Charlottesville |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.